Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Sat, 10.12.2022
MorphoSys AG
Media Release
PLANEGG/MUNICH, Germany, December 10, 2022
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Final analysis from the Phase 1b firstMIND trial shows no new safety signals and provides additional information on progression-free survival at 24 months for pat [ … ]
Sat, 10.12.2022
MorphoSys AG
Media Release
PLANEGG/MUNICH, Germany, December 10, 2022
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Final analysis from the Phase 1b firstMIND trial shows no new safety signals and provides additional information on progression-free survival at 24 months for pat [ … ]
Tue, 06.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 6, 2022
MorphoSys Out Licenses Pre-Clinical Oncology Program
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target
MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net s [ … ]
Tue, 06.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 6, 2022
MorphoSys Out Licenses Pre-Clinical Oncology Program
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target
MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net s [ … ]
Mon, 28.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 28, 2022
MorphoSys AG: Financial Calendar 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) publishes its financial calendar dates for the year 2023:
Publication of Interim Statement / Report
Conference Call
Year-End Results 2022
March 15, 2023 // 9:00 pm CET
(4:00 pm EDT; 8:00 pm G [ … ]
Mon, 28.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 28, 2022
MorphoSys AG: Financial Calendar 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) publishes its financial calendar dates for the year 2023:
Publication of Interim Statement / Report
Conference Call
Year-End Results 2022
March 15, 2023 // 9:00 pm CET
(4:00 pm EDT; 8:00 pm G [ … ]
Wed, 16.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 16, 2022
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022
Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential [ … ]
Wed, 16.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 16, 2022
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022
Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential [ … ]
Mon, 14.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 14, 2022
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
GRADUATE studies did not meet primary endpoint
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OT [ … ]
Mon, 14.11.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 14, 2022
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
GRADUATE studies did not meet primary endpoint
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OT [ … ]